Latest Breaking News On - Pharma team - Page 7 : comparemela.com
Tiziana Life Sciences plc (via Public) / Interim Results for the Six Months Ended 30 June 2021 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
BostonMassachusettsUnited-statesJapanBrazilCanadaLondonCity-ofUnited-kingdomTakanawaTokyoBermudaTiziana seeks partner in Asia to enhance hepatocellular carcinoma treatment
Tiziana seeks partner in Asia to enhance hepatocellular carcinoma treatment 05 May 2021 | News
Source credit: Shutterstock
Tiziana Life Sciences plc, a UK based biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan KK, Pharma Team, for a strategic business development plan to identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients.
Previously, Tiziana successfully completed a Phase 2 clinical trial with orally administered Milciclib in sorafenib-resistant or intolerant HCC patients. The clinical data, presented at the American Society of Clinical Oncology (ASCO), demonstrated that the treatment was well-tolerated and produced clinical activity. Recently, a patent co
Japan
United-states
United-kingdom
Takanawa
Tokyo
American
Tiziana-life-sciences
American-society-of-clinical-oncology
Pharma-team
Takanawa-japan
American-society
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma. Tiziana Life Sciences Plc London, UNITED KINGDOM
Objective of this partnership with Takanawa Japan K.K., Pharma Team, is to identify a strategic partner in Japan for further development of Milciclib either alone or in combination with a tyrosine kinase inhibitor (TKI) for treatment of advanced HCC patients in Asian countries where prevalence of HCC is high, and the available therapeutic options are not entirely satisfactory.
Milciclib, a broad-spectrum cyclin dependent kinase (pan-CDK) inhibitor, has successfully completed eight phase 1 and phase 2 trials in thymic carcinoma, thymoma and hepatocellular carcinoma (HCC), showing tolerability and positive clinical responses.
Japan
Takanawa
Tokyo
Pharma-team
ஜப்பான்
தகானாவ
டோக்கியோ
பார்மா-அணி